ProMIS Neurosciences, based in Toronto, develops precision medicine for neurodegenerative diseases, focusing on antibody therapeutics targeting misfolded proteins. The company went public on April 3, 2017, and employs six full-time staff.
19 Promis Title bought 539,100 shares of PMN on 29 July at $0.00 per share, worth a total of $0. They now own 539,100 PMN shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
